Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.

OBJECTIVES: Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccines on a large, national scale. METHODS: The Vaccine Adverse Event Reporting System was filtered for cutaneous and hair and nail reactions to the COVID-19 vaccines. Patient demographics and past medical histories, vaccine manufacturer and dosing, symptom timing, reaction location, and patient outcomes were extracted from each report. RESULTS: As of December 24, 2021, there were 67,273 cutaneous reactions to all COVID-19 vaccines, with most patients receiving the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. The most common reactions overall were injection-site reaction, urticaria, and papular rash, with injection-site reaction more common after the Moderna (mRNA-1273) vaccine, and all other cutaneous reactions more common after the Pfizer-BioNTech (BNT162b2) vaccine. Patients with past histories of psoriasis, urticaria, and local site reactions to a vaccine were more likely to report these same symptoms after the COVID-19 vaccine. CONCLUSION: Patients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective.

Review of Telemedicine for Management of Acne Patients.

Accelerated by the COVID-19 pandemic, telemedicine has changed the landscape of dermatology practice. This manuscript aims to review the role of telemedicine in acne management and provide management recommendations. A literature search of the PubMed and Scopus databases was conducted using keywords "acne," "telemedicine," "teledermatology," "telehealth," "virtual," and "video." Eight articles directly related to telemedicine and acne management were included in the study. In-person vs. telemedicine management of acne patients had high diagnostic concordance and similar efficacy and remission rates. Survey-based studies of acne patients reported high interest and satisfaction and no safety concerns with acne management via telemedicine. Telemedicine was reported as an effective triage tool. Prescription patterns for acne medications during telemedicine vs. in-person visits varied. It is likely that dermatologists will continue to treat acne and other common skin conditions via teledermatology. Therefore, it is important for dermatologists to gain comfort in utilizing virtual visits to diagnose and manage acne patients. Further studies are needed to establish a standardized structural framework for telemedicine visits to optimize patient care and outcomes for acne patients.

Deferring Nail Mycological Sampling during the COVID-19 Pandemic: Recommendations from a Multidisciplinary Panel of Nail Specialists.

Onychomycosis is the most common nail condition seen in clinical practice, with significant impact on quality of life. Clinical examination alone is insufficient for accurate diagnosis, but mycological confirmation can be challenging during the COVID-19 pandemic. In this letter, a multidisciplinary panel of dermatologists, a podiatrist, dermatopathologists, and a mycologist, discuss considerations for mycological sampling during the pandemic.